Investor Presentaiton
33
Innovative Medicines EUR 235.1 million (-28.6%)
NubeqaⓇsales more than doubled in 2023
-
MEUR
NubeqaⓇ sales booked by Orion¹
70
60
50
40
30
20
10
10
0
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2019
2020
2021
2023
•
•
•
ORION
Decline due to significant EUR 228 million upfront
payment recorded in 2022
•
Excluding the upfront payment, net sales more than
doubled
2023 sales includes EUR 30 million NubeqaⓇ sales
milestone
NubeqaⓇ sales booked by Orion EUR 182.5 million
(>100%) in 2023
Marinus received EU approval for ganaxolone²
(brand name Ztalmy®) - Orion is focusing on
making ganaxolone available for patients in Europe
and has pricing and reimbursement processes
planned or underway in Europe
Product sales to Bayer
2022
Royalty
¹Orion's sales to Bayer for commercial use + royalties from Bayer
Investor Presentation Orion Corporation
2 oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-
dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of age.
Treatment may be continued in patients 18 years of age and older.View entire presentation